Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, BioGenex Extend Assay Deal

NEW YORK (GenomeWeb News) – BioGenex today said that Abbott has extended a technology co-development and distribution agreement covering marketing of the firm's Xmatrx platform for the automation of Abbott's fluorescence in situ hybridization (FISH) product line.

Under the deal, Abbott's customers have the option to run immunohistochemistry and in-situ hybridization assays on the Xmatrx, and BioGenex customers can run FISH assays on its system. The Xmatrx system facilitates "automation of advanced molecular staining assays, from Microtome to Microscope," BioGenex CEO Krishan Kalra said in a statement.

The Xmatrx will be co-branded and marketed under a co-exclusive distribution pact, which calls for the firms to further collaborate on getting customers to adopt FISH, IHC, and ISH as primary tools in molecular diagnostics and personalized medicine, said BioGenex.

San Ramon, Calif.-based BioGenex said that it will receive a multi-year minimum volume commitment from Abbott, under terms of the agreement. Further terms of the deal were not disclosed.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.